Author

Wayne Holman

Institution: Chrysalis BioTherapeutics (United States)

Observed institutions: Emory University, HistoryMiami, Chrysalis BioTherapeutics (United States)

ORCID: 0000-0003-2163-3707

Observed ORCID: 0000-0003-2163-3707

OpenAlex ID: A5034070895

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

2021 · William A. Fischer, Joseph J. Eron, et al. · Science Translational Medicine · 547

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2

2021 · Wendy P. Painter, Wayne Holman, et al. · Antimicrobial Agents and Chemotherapy · 404

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

2021 · Saye H Khoo, Richard Fitzgerald, et al. · Journal of Antimicrobial Chemotherapy · 123

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

2022 · Saye H Khoo, Richard FitzGerald, et al. · The Lancet Infectious Diseases · 83

Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2

2021 · Wendy Holman, Wayne Holman, et al. · Trials · 53

Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

2022 · Richard FitzGerald, Laura Dickinson, et al. · Clinical Infectious Diseases · 25

Population pharmacokinetics of molnupiravir in adults with COVID ‐19: Lack of clinically important exposure variation across individuals

2023 · Sébastien Bihorel, Youfang Cao, et al. · CPT Pharmacometrics & Systems Pharmacology · 10

Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID ‐19

2025 · Akshita Chawla, Ruthie Birger, et al. · Clinical and Translational Science · 1

The Antiviral Mechanism of Action of Molnupiravir in Humans with COVID-19

2023 · Timothy P. Sheahan, Laura J. Stevens, et al. · medRxiv · 1

Accelerated First-in-Human Clinical Trial of EIDD-2801/MK-4482 (molnupiravir), a Ribonucleoside Analogue with Potent Antiviral Activity Against SARS-CoV-2

2021 · Oren Cohen, Wendy Holman, et al. · Research Square · 1

Works count: 10

Citation count: 1,248

H-index: 7

I10-index: 7